Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Buy
79
CMPX Quote, Financials, Valuation and Earnings
Last price:
$6.29
Seasonality move
:
-7.27%
Day range:
$6.21 - $6.60
52-week range:
$1.33 - $6.88
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.33x
Volume:
2.5M
Avg. volume:
2.4M
1-year change:
82.03%
Market cap:
$1.1B
Revenue:
$850K
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
-- | -$0.09 | -100% | -19.64% | $13.46 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$111.5M | $0.09 | 49.53% | -88.43% | $31.75 |
|
BHVN
Biohaven Ltd.
|
-- | -$0.96 | -- | -59.82% | $20.94 |
|
IBRX
ImmunityBio, Inc.
|
$37.8M | -$0.10 | 168.1% | -50.66% | $11.80 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.61% | 137.25% | $1,201.63 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.75 | 14.08% | 25.96% | $868.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
$6.28 | $13.46 | $1.1B | -- | $0.00 | 0% | -- |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$25.86 | $31.75 | $3.2B | -- | $0.00 | 0% | 10.39x |
|
BHVN
Biohaven Ltd.
|
$11.36 | $20.94 | $1.5B | -- | $0.00 | 0% | -- |
|
IBRX
ImmunityBio, Inc.
|
$5.95 | $11.80 | $5.9B | -- | $0.00 | 0% | 61.62x |
|
LLY
Eli Lilly & Co.
|
$1,040.00 | $1,201.63 | $981.1B | 46.04x | $1.73 | 0.6% | 14.54x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$803.17 | $868.04 | $84.9B | 19.32x | $0.88 | 0.44% | 6.08x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
4.5% | 3.772 | 1.59% | 17.72x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.523 | 5.02% | 3.07x |
|
BHVN
Biohaven Ltd.
|
105.78% | 1.224 | 19.78% | 2.31x |
|
IBRX
ImmunityBio, Inc.
|
255.62% | 1.674 | 35.53% | 5.07x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.536 | 4.56% | 0.71x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.69% | -0.011 | 3.64% | 3.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CMPX
Compass Therapeutics, Inc.
|
-$371K | -$15.8M | -45.93% | -48.62% | -1770% | -$10.9M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
BHVN
Biohaven Ltd.
|
-$1.1M | -$169.4M | -213.94% | -349.4% | -- | -$145.7M |
|
IBRX
ImmunityBio, Inc.
|
$27.9M | -$55.6M | -122.87% | -- | -173.51% | -$69.7M |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.2B | $898.6M | 13.66% | 14.93% | 23.13% | $880M |
Compass Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CMPX or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 7.47%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About CMPX or ARQT?
Compass Therapeutics, Inc. has a consensus price target of $13.46, signalling upside risk potential of 114.36%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.75 which suggests that it could grow by 22.78%. Given that Compass Therapeutics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.12 0 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is CMPX or ARQT More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.702, suggesting its more volatile than the S&P 500 by 70.199%.
-
Which is a Better Dividend Stock CMPX or ARQT?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or ARQT?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 10.39x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M ARQTArcutis Biotherapeutics, Inc.10.39x -- $99.2M $7.4M
-
Which has Higher Returns CMPX or BHVN?
Biohaven Ltd. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of --. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Biohaven Ltd.'s return on equity of -349.4%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M BHVNBiohaven Ltd.-- -$1.64 $297M -
What do Analysts Say About CMPX or BHVN?
Compass Therapeutics, Inc. has a consensus price target of $13.46, signalling upside risk potential of 114.36%. On the other hand Biohaven Ltd. has an analysts' consensus of $20.94 which suggests that it could grow by 84.31%. Given that Compass Therapeutics, Inc. has higher upside potential than Biohaven Ltd., analysts believe Compass Therapeutics, Inc. is more attractive than Biohaven Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.12 0 0 BHVNBiohaven Ltd.9 5 0 -
Is CMPX or BHVN More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biohaven Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CMPX or BHVN?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biohaven Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Biohaven Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or BHVN?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Biohaven Ltd. quarterly revenues of --. Compass Therapeutics, Inc.'s net income of -$14.3M is higher than Biohaven Ltd.'s net income of -$173.4M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Biohaven Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus -- for Biohaven Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M BHVNBiohaven Ltd.-- -- -- -$173.4M
-
Which has Higher Returns CMPX or IBRX?
ImmunityBio, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -209.83%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat ImmunityBio, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M IBRXImmunityBio, Inc.87.13% -$0.07 $337.8M -
What do Analysts Say About CMPX or IBRX?
Compass Therapeutics, Inc. has a consensus price target of $13.46, signalling upside risk potential of 114.36%. On the other hand ImmunityBio, Inc. has an analysts' consensus of $11.80 which suggests that it could grow by 98.49%. Given that Compass Therapeutics, Inc. has higher upside potential than ImmunityBio, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than ImmunityBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.12 0 0 IBRXImmunityBio, Inc.4 0 0 -
Is CMPX or IBRX More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ImmunityBio, Inc. has a beta of 0.020, suggesting its less volatile than the S&P 500 by 98.006%.
-
Which is a Better Dividend Stock CMPX or IBRX?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ImmunityBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. ImmunityBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CMPX or IBRX?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than ImmunityBio, Inc. quarterly revenues of $32.1M. Compass Therapeutics, Inc.'s net income of -$14.3M is higher than ImmunityBio, Inc.'s net income of -$67.3M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while ImmunityBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 61.62x for ImmunityBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M IBRXImmunityBio, Inc.61.62x -- $32.1M -$67.3M
-
Which has Higher Returns CMPX or LLY?
Eli Lilly & Co. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 34.4%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About CMPX or LLY?
Compass Therapeutics, Inc. has a consensus price target of $13.46, signalling upside risk potential of 114.36%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,201.63 which suggests that it could grow by 15.54%. Given that Compass Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Compass Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.12 0 0 LLYEli Lilly & Co.18 6 0 -
Is CMPX or LLY More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock CMPX or LLY?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.6% to investors and pays a quarterly dividend of $1.73 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CMPX or LLY?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 46.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 14.54x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M LLYEli Lilly & Co.14.54x 46.04x $19.3B $6.6B
-
Which has Higher Returns CMPX or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 21.74%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital CMPXCompass Therapeutics, Inc.-- -$0.08 $219.5M REGNRegeneron Pharmaceuticals, Inc.81.22% $7.86 $34.2B -
What do Analysts Say About CMPX or REGN?
Compass Therapeutics, Inc. has a consensus price target of $13.46, signalling upside risk potential of 114.36%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Compass Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CMPXCompass Therapeutics, Inc.12 0 0 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is CMPX or REGN More Risky?
Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.
-
Which is a Better Dividend Stock CMPX or REGN?
Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CMPX or REGN?
Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CMPXCompass Therapeutics, Inc.-- -- -- -$14.3M REGNRegeneron Pharmaceuticals, Inc.6.08x 19.32x $3.9B $844.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Is Sandisk The Next Big Memory Stock?
Computer memory manufacturer Sandisk (NASDAQ:SNDK) has quietly been one of…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
77
CPS alert for Feb 14
Cooper-Standard Holdings, Inc. [CPS] is up 32.06% over the past day.
Buy
58
TPH alert for Feb 14
Tri Pointe Homes, Inc. [TPH] is up 26.83% over the past day.
Sell
20
IRON alert for Feb 14
Disc Medicine, Inc. [IRON] is down 21.88% over the past day.
